注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
MaxCyte Inc(MaxCyte)是一家生命科學公司。該公司專注於推進細胞療法的發現、開發和商業化。該公司為從事藥物發現和開發、生物製造和細胞治療(包括基因編輯和免疫腫瘤學)的生物製藥合作夥伴提供細胞工程平台。MaxCyte已開發並商業化可促進各種細胞的工程化的Flow Electroporation平台。該公司的ExPERT平台基於Flow Electroporation技術,旨在應對不斷擴大的細胞治療市場,並用於整個細胞治療領域。ExPERT系列產品包括:ATx、STx和GTx三款儀器。MaxCyte還開發了一種基於將mRNA轉染到未受刺激的細胞中以開發免疫細胞療法的治療平台CARMA。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Richard Huntington Douglas | 69 | 2018 | Independent Non-Executive Chairman of the Board |
William W. Brooke | 67 | 2004 | Independent Non-Executive Director |
Arthur Michael Mandell | 71 | 2006 | Independent Non-Executive Director |
Stanley Charles Erck | 76 | 2005 | Independent Non-Executive Director |
John Joseph Johnston | 65 | 2016 | Independent Non-Executive Director |
Rekha Hemrajani | 55 | 2021 | Independent Non-Executive Director |
Yasir B. Al-Wakeel | 42 | 2021 | Independent Non-Executive Director |
Cenk Sumen | 50 | 2022 | Member of Scientific Advisory Board |
Nako Nakatsuka | - | 2023 | Member of Scientific Advisory Board |
Oliver Rando | - | 2023 | Member of Scientific Advisory Board |
Patrick J. Balthrop | 67 | 2022 | Independent Non-Executive Director |
Marcela V. Maus | 48 | 2023 | Member of Scientific Advisory Board |
Avery Posey | - | 2023 | Member of Scientific Advisory Board |
Maher Masoud | 48 | 2017 | President, CEO & Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核